A trial of a neuropsychiatric drug in children with autism has found that it significantly improves cognitive function, while reducing symptoms of the disorder.
The trial of MDPV, an older version of the anti-inflammatory drug methotrexate, compared the drug with a placebo in a study of 717 children aged 4-11.
It found that the MDPVP led to an improvement in children’s behaviour, while not affecting their cognition.
The researchers said their results suggest that a combination of MNPV and anti-psychotic drugs might be more effective than either alone.
They also found that MDPVB led to fewer seizures and reduced symptoms of autism spectrum disorder (ASD), which can cause symptoms such as social isolation, anxiety and aggression.
Dr Paul Epple, who led the study, said: “The combination of a drug that is very good at improving cognitive function and helping children to be able to interact more socially is really important in this age group.”
This is really good news because it shows the potential of this drug to be effective in these children.
“A study of another anti-nausea drug, methotropterone acetate, showed similar results.
Dr Epples study looked at the impact of a combination drug with anti-inflammatories and autism-spectrum drugs.
He said the combination of the drugs had “quite dramatic” effects on the children’s cognitive function.”
The combination has been shown to have a profound effect on the cognition, mood and behaviour of children with ASD,” he said.”
In fact, there was no effect on any of the other measures of cognitive function measured by the children.
“He said it was also clear that the combination drug was most effective at treating ASD in children who were already on anti-chronic anti-receptor drugs, but that the anti the drugs were also able to help some children with the condition.”
If you take the anti medication alone, you can have an effect on cognition and mood, but if you take this combination, you really need a combination to have an impact on ASD symptoms,” he explained.”
But we don’t know what combination works best for those children.
“The trial was conducted in partnership with the Australian Research Council-funded Australian Centre for Autism Research and the University of Melbourne’s Centre for Neurodevelopmental and Neuropsychological Genetics.
The research was funded by the National Institute for Health Research, the Victorian Government and the Australian Health and Medical Research Council.
Topics:drugs-and-substance-abuse,medical-research,health,vaccines-and/or-health-care,nephrology,research,medicines-government-and,health-policy,medecine,autism,australiaMore stories from Victoria